Storyline
FDA restarts review of Capricor’s Duchenne cell therapy as Xenon reports strong epilepsy results
Xenon Pharmaceuticals saw its shares surge nearly 50% after reporting epilepsy trial results that exceeded Wall Street expectations.
Evidence locked
Today's free sample is only available for the edition's flagship storyline.
Evidence preview
- Xenon epilepsy and Capricor FDA review newsBioPharma Dive
- FDA reconsidering Capricor’s Duchenne cell therapyFierce Biotech